After the administration of cytostatic drugs, an increase in thromboembolic phenomena has
been described in cancer patients. The authors studied the changes in plasmatic …

Evidence for “hypercoagulability” is commonly found in patients with cancer and increases
the risk of thromboembolism (TE)[1]. While the pathophysiology of TE in cancer is complex, it …

The accumulation of fibrin/fibrinogen and other coagulation factors in and around solid
tumors and metastatic foci has been recognized for a century as an aspect of cancer …

The association of venous thrombosis and cancer has been recognized for over 40 years
and its description first attributed to Armand Trousseau [1], who later made the diagnosis on …

It is now recognized that the hemostatic system plays an important role in cancer growth and
dissemination, processes known to be vitally dependent on new tumor blood vessel …

Cancer cells may promote fibrin formation in the tumor microenvironment through availability
of procoagulant activities which are mainly of two types: tissue thrombo plastin-like or direct …

In view of the possible role of platelets and coagulation mechanisms in the growth and
dissemination of solid tumors, a number of hematological parameters were followed during …

Numerous investigators, both in clinical and basic sciences, have postulated that platelets,
platelet thrombi and/or the coagulation cascade play a role in metastasis of tumor cells …

Substantial epidemiologic, laboratory, pathologic and clinical evidence supports the historic
association between activation of blood coagulation and progression of cancer. The …

The relationship between hemostasis and malignancy is well recognized, with both
elements interacting in a “vicious cycle” where cancers overexpress procoagulants and …